Beretta G, Bonadonna G, Bajetta E, Tancini G, De Lena M, Azzarelli A, Veronesi U
Cancer Treat Rep. 1976 Feb;60(2):205-11.
The results of three controlled studies with multiple-drug regimens which included DTIC are reported for advanced melanoma, soft tissue sarcomas, and Hodgkin's disease. In malignant melanoma, no statistical difference was observed between (a) DTIC, BCNU, and vincristine, and (b) DTIC, BCNU, and actinomycin D in terms of response rate, median duration of response, and survival. In sarcomas, the combination of adriamycin and DTIC produced a higher incidence of complete plus partial responders when compared to cyclophosphamide, vincristine, and methotrexate. However, no significant difference was seen in the median duration of response or survival. In Hodgkin's disease, a new four-drug combination including adriamycin, bleomycin, vinblastine, and DTIC (ABVD) produced an incidence of complete remissions and a median duration of response comparable to that achieved with mechlorethamine, vincristine (Oncovin), predinisone, and procarbazine (MOPP). Preliminary data indicate that ABVD is not cross resistant to MOPP. It is concluded that DTIC can be successfully and safely employed in combination with conventional agents in susceptible neoplastic diseases.
本文报告了三项针对晚期黑色素瘤、软组织肉瘤和霍奇金病的多药联合对照研究结果，这些研究方案均包含达卡巴嗪（DTIC）。在恶性黑色素瘤中，就缓解率、中位缓解持续时间和生存率而言，（a）达卡巴嗪、卡莫司汀（BCNU）和长春新碱，与（b）达卡巴嗪、卡莫司汀和放线菌素D之间未观察到统计学差异。在肉瘤中，与环磷酰胺、长春新碱和甲氨蝶呤相比，阿霉素与达卡巴嗪联合使用时完全缓解加部分缓解的发生率更高。然而，在中位缓解持续时间或生存率方面未观察到显著差异。在霍奇金病中，一种新的四药联合方案，即阿霉素、博来霉素、长春碱和达卡巴嗪（ABVD），其完全缓解率和中位缓解持续时间与氮芥、长春新碱（Oncovin）、泼尼松和丙卡巴肼（MOPP）方案相当。初步数据表明，ABVD与MOPP不存在交叉耐药性。结论是，在易感的肿瘤性疾病中，达卡巴嗪可与传统药物成功且安全地联合使用。
